OOIR: Observatory of International Research

Papers

(The H4-Index of Liver International is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Liver injury during highly pathogenic human coronavirus infections	609
Comparison of MAFLD and NAFLD diagnostic criteria in real world	343
Liver impairment in COVID‐19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China	318
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD	263
Pathophysiological mechanisms of liver injury in COVID‐19	254
COVID‐19 and liver disease	227
Clinical characteristics of non‐ICU hospitalized patients with coronavirus disease 2019 and liver injury: A retrospective study	210
Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations	206
What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’	196
Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review	150
Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population	131
Targeting ferroptosis alleviates methionine‐choline deficient (MCD)‐diet induced NASH by suppressing liver lipotoxicity	126
Coronavirus disease 2019 and prevalence of chronic liver disease: A meta‐analysis	120
Impact of chronic liver disease on outcomes of hospitalized patients with COVID‐19: A multicentre United States experience	108
The global epidemiology of hepatitis E virus infection: A systematic review and meta‐analysis	107
Changing epidemiology of hepatocellular carcinoma in Asia	98
Abnormal liver function tests predict transfer to intensive care unit and death in COVID‐19	94
First case of drug‐induced liver injury associated with the use of tocilizumab in a patient with COVID‐19	88
SARS‐CoV‐2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID‐19	85
Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis	78
Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis	75
Hepatic macrophages: Key players in the development and progression of liver fibrosis	74
Metabolic‐associated fatty liver disease is associated with severity of COVID‐19	72
Intestinal permeability in human nonalcoholic fatty liver disease: A systematic review and meta‐analysis	71
The changing scenario of hepatocellular carcinoma in Italy: an update	66

Radiomics in liver diseases: Current progress and future opportunities	65
Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts	62
Bilirubin levels in patients with mild and severe Covid‐19: A pooled analysis	60
Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta‐analysis: Focusing on the non‐overlap groups	60
Diet and exercise in NAFLD/NASH: Beyond the obvious	59
Hepatitis E: An update on One Health and clinical medicine	58
The NAFLD‐MAFLD debate: Eminence vs evidence	58
Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)	56
Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID‐19	56
Characterization of the gut‐liver‐muscle axis in cirrhotic patients with sarcopenia	50
Nonalcoholic fatty liver disease is associated with increased risk of atrial fibrillation	49
PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH	48
Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib	48
Ultra‐processed food is associated with features of metabolic syndrome and non‐alcoholic fatty liver disease	45
Consensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group	45
Cardiodynamic state is associated with systemic inflammation and fatal acute‐on‐chronic liver failure	45
Treatment and the prognosis of hepatocellular carcinoma in Asia	44
MR elastography‐based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study	43
LncRNA NEAT1: Shedding light on mechanisms and opportunities in liver diseases	43